Accepted at 9:17 p.m. Oct, 31, 2023 by Alex
Author: ThomasHollan
Related Note: 1489968541246
Rationale for change

The / made it not clear that IL-12 and IL-23 are separate targets and not the same molecule.

So changed it to IL-12 and IL-23

Text Text
Extra
- IL-12 stimulates TH1 cells, IL-23 leads to stimulation of gamma-delta T cells

- IL-23 stimulates Th17 cells which leads to Crohn, UC, and psoriasis/psoriatic arthritis. IL-23 also leads to stimulation of gamma-delta T cells which is important for the development of psoriatic arthritis.

- Newly approved treatment for UC. IL-23 is considered the central cytokine in Crohn and possibly UC (blocked by tildrakizumab)
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Empty field
Sketchy 2

Watch Seronegative Spondyloarthritis DDx
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
Watch associated Bootcamp video - Transplant Rejection: Biologic Immunotherapy

Watch associated Bootcamp video - Psoriatic Arthritis

Watch associated Bootcamp video - Inflammatory Disease of the Skin: Red Plaque Disease

Watch associated Bootcamp video - Pharmacology : TNF-a Inhibitors and Monoclonal Antibodies
OME

Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#OME::PreClinical::Immunology #AK_Step1_v12::^Other::^HighYield::2-RelativelyHighYield #AK_Step1_v12::#Bootcamp::Musculoskeletal::04_Seronegative_Spondyloarthritis::02_Psoriatic_Arthritis #AK_Step1_v12::#SketchyPharm::Immunology-&-Biochemistry-Pharmacology::Immuno-suppressives::General-Immunotherapy #AK_Step1_v12::#Bootcamp::Dermatology::03_Inflammatory_Diseases_of_the_Skin::05_Red_Plaque_Disease #AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Bootcamp::Immunology::13_Transplant_Rejection::08_Biologic_Immunotherapy !AK_UpdateTags::Step1decks::Zanki-Pharmacology #AK_Step1_v12::^Other::^EXPN #AK_Step1_v12::#B&B::14_MSK::03_Pathology::09_Seronegative_Spondyloarthritis #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies::Ustekinumab #AK_Step2_v12::#SketchyIM::07_Rheumatology::04_Seronegative_DIsorders::01_Seronegative_Spondyloarthritis_DDx #AK_Step1_v12::#Bootcamp::Musculoskeletal::15_Pharmacology::07_TNF_Alpha_Inhibitors_And_Monoclonal_Antibodies #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies